Toxicology Strategies for Drug Discovery: Present and Future

Chemical Research in Toxicology

Volumn 29, Issue 4, 2016, Pages 473-504

  Blomme, Eric A G ^a   Will, Yvonne ^b  

^a ABBVIE INC   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR TOXICITY; COMPUTER MODEL; DRUG CYTOTOXICITY; DRUG DEVELOPMENT; FUTUROLOGY; GENE MUTATION; GENETIC TOXICOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; INDUCED PLURIPOTENT STEM CELL; MITOCHONDRIAL TOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRECLINICAL STUDY; PROTEIN INTERACTION; REVIEW; TOXICOLOGY; ZEBRA FISH; ANIMAL; BIOLOGICAL MODEL; BIOLOGY; CHEMISTRY; COMPUTER SIMULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; METABOLISM; PROCEDURES; TOXICITY TESTING;

DRUG; PROTEIN;

ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEINS; TOXICITY TESTS;

EID: 84964688061     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/acs.chemrestox.5b00407     Document Type: Review

References (240)

1. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., and Rosenthal, J. (2014) Clinical development success rates for investigational drugs Nat. Biotechnol. 32, 40-51 10.1038/nbt.2786
2. Munos, B. (2009) Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discovery 8, 959-968 10.1038/nrd2961
3. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, M. N. (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework Nat. Rev. Drug Discovery 13, 419-431 10.1038/nrd4309
4. DiMasi, J. A., Feldman, L., Seckler, A., and Wilson, A. (2010) Trends in risks associated with new drug development: success rates for investigational drugs Clin. Pharmacol. Ther. 87, 272-277 10.1038/clpt.2009.295
5. Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., and Weir, A. (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat. Rev. Drug Discovery 14, 475-486 10.1038/nrd4609
6. Leeson, P. D. and St-Gallay, S. A. (2011) The influence of the 'organizational factor' on compound quality in drug discovery Nat. Rev. Drug Discovery 10, 749-765 10.1038/nrd3552
7. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., and Heller, A. (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals Regul. Toxicol. Pharmacol. 32, 56-67 10.1006/rtph.2000.1399
8. Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A. V., Toft, D. B., and Mow, T. (2014) Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how Drug Discovery Today 19, 1131-1136 10.1016/j.drudis.2013.12.008
9. Stevens, J. L. and Baker, T. K. (2009) The future of drug safety testing: expanding the view and narrowing the focus Drug Discovery Today 14, 162-167 10.1016/j.drudis.2008.11.009
10. Reinhart, G. A., Fryer, R. M., Osinski, M. A., Polakowski, J. S., Cox, B. F., and Gintant, G. A. (2005) Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward Curr. Opin. Chem. Biol. 9, 392-399 10.1016/j.cbpa.2005.05.003
11. Ewart, L., Aylott, M., Deurinck, M., Engwall, M., Gallacher, D. J., Geys, H., Jarvis, P., Ju, H., Leishman, D., Leong, L., McMahon, N., Mead, A., Milliken, P., Suter, W., Teisman, A., Van Ammel, K., Vargas, H. M., Wallis, R., and Valentin, J. P. (2014) The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative Toxicol. Sci. 142, 427-435 10.1093/toxsci/kfu198
12. Khatri, P., Sirota, M., and Butte, A. J. (2012) Ten years of pathway analysis: current approaches and outstanding challenges PLoS Comput. Biol. 8, e1002375 10.1371/journal.pcbi.1002375
13. Fedele, C., Riccio, G., Malara, A. E., D'Alessio, G., and De Lorenzo, C. (2012) Mechanisms of cardiotoxicity associated with ErbB2 inhibitors Breast Cancer Res. Treat. 134, 595-602 10.1007/s10549-012-2103-8
14. Melosky, B., Leighl, N. B., Rothenstein, J., Sangha, R., Stewart, D., and Papp, K. (2015) Management of egfr tki-induced dermatologic adverse events Curr. Oncol 22, 123-132 10.3747/co.22.2430
15. Reilly, E. B., Phillips, A. C., Buchanan, F. G., Kingsbury, G., Zhang, Y., Meulbroek, J. A., Cole, T. B., DeVries, P. J., Falls, H. D., Beam, C., Gu, J., Digiammarino, E. L., Palma, J. P., Donawho, C. K., Goodwin, N. C., and Scott, A. M. (2015) Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody Mol. Cancer Ther. 14, 1141-1151 10.1158/1535-7163.MCT-14-0820
16. Gavva, N. R. (2008) Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1 Trends Pharmacol. Sci. 29, 550-557 10.1016/j.tips.2008.08.003
17. Reilly, R. M., McDonald, H. A., Puttfarcken, P. S., Joshi, S. K., Lewis, L., Pai, M., Franklin, P. H., Segreti, J. A., Neelands, T. R., Han, P., Chen, J., Mantyh, P. W., Ghilardi, J. R., Turner, T. M., Voight, E. A., Daanen, J. F., Schmidt, R. G., Gomtsyan, A., Kort, M. E., Faltynek, C. R., and Kym, P. R. (2012) Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature J. Pharmacol. Exp. Ther. 342, 416-428 10.1124/jpet.111.190314
18. Voight, E. A., Gomtsyan, A. R., Daanen, J. F., Perner, R. J., Schmidt, R. G., Bayburt, E. K., DiDomenico, S., McDonald, H. A., Puttfarcken, P. S., Chen, J., Neelands, T. R., Bianchi, B. R., Han, P., Reilly, R. M., Franklin, P. H., Segreti, J. A., Nelson, R. A., Su, Z., King, A. J., Polakowski, J. S., Baker, S. J., Gauvin, D. M., Lewis, L. R., Mikusa, J. P., Joshi, S. K., Faltynek, C. R., Kym, P. R., and Kort, M. E. (2014) Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)ur ea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy J. Med. Chem. 57, 7412-7424 10.1021/jm500916t
19. Meanwell, N. A. (2011) Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24, 1420-1456 10.1021/tx200211v
20. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., and Meier, P. J. (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver Gastroenterology 118, 422-430 10.1016/S0016-5085(00)70224-1
21. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24, 1345-1410 10.1021/tx200168d
22. Snow, K. L. and Moseley, R. H. (2007) Effect of thiazolidinediones on bile acid transport in rat liver Life Sci. 80, 732-740 10.1016/j.lfs.2006.11.001
23. Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., and Hamadeh, H. K. (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development Toxicol. Sci. 136, 216-241 10.1093/toxsci/kft176
24. Hann, M. M. (2011) Molecular obesity, potency and other addictions in drug discovery MedChemComm 2, 349-355 10.1039/c1md00017a
25. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 46, 3-26 10.1016/S0169-409X(00)00129-0
26. Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., Decrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L., and Zhang, Y. (2008) Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18, 4872-4875 10.1016/j.bmcl.2008.07.071
27. Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., and Urban, L. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data ChemMedChem 2, 874-880 10.1002/cmdc.200700036
28. Leeson, P. D. and Springthorpe, B. (2007) The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 6, 881-890 10.1038/nrd2445
29. Peters, J. U., Schnider, P., Mattei, P., and Kansy, M. (2009) Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds ChemMedChem 4, 680-686 10.1002/cmdc.200800411
30. Sutherland, J. J., Raymond, J. W., Stevens, J. L., Baker, T. K., and Watson, D. E. (2012) Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes J. Med. Chem. 55, 6455-6466 10.1021/jm300684u
31. Muthas, D., Boyer, S., and Hasselgren, C. (2013) A critical assessment of modeling safety-related drug attrition MedChemComm 4, 1058-1065 10.1039/c3md00072a
32. Lovering, F., Bikker, J., and Humblet, C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52, 6752-6756 10.1021/jm901241e
33. Kenny, P. W. and Montanari, C. A. (2013) Inflation of correlation in the pursuit of drug-likeness J. Comput.-Aided Mol. Des. 27, 1-13 10.1007/s10822-012-9631-5
34. Argese, E., Bettiol, C., Giurin, G., and Miana, P. (1999) Quantitative structure-activity relationships for the toxicity of chlorophenols to mammalian submitochondrial particles Chemosphere 38, 2281-2292 10.1016/S0045-6535(98)00446-9
35. Naven, R. T., Swiss, R., Klug-McLeod, J., Will, Y., and Greene, N. (2013) The development of structure-activity relationships for mitochondrial dysfunction: uncoupling of oxidative phosphorylation Toxicol. Sci. 131, 271-278 10.1093/toxsci/kfs279
36. Huth, J. R., Song, D., Mendoza, R. R., Black-Schaefer, C. L., Mack, J. C., Dorwin, S. A., Ladror, U. S., Severin, J. M., Walter, K. A., Bartley, D. M., and Hajduk, P. J. (2007) Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance Chem. Res. Toxicol. 20, 1752-1759 10.1021/tx700319t
37. Raunio, H. (2011) In silico toxicology-non-testing methods Front. Pharmacol. 2, 33 10.3389/fphar.2011.00033
38. Baell, J. B. and Holloway, G. A. (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53, 2719-2740 10.1021/jm901137j
39. Metz, J. T., Huth, J. R., and Hajduk, P. J. (2007) Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups J. Comput.-Aided Mol. Des. 21, 139-144 10.1007/s10822-007-9109-z
40. Pinto, M., Digles, D., and Ecker, G. F. (2014) Computational models for predicting the interaction with ABC transporters Drug Discovery Today: Technol. 12, e69-e77 10.1016/j.ddtec.2014.03.007
41. Snyder, R. D. and Smith, M. D. (2005) Computational prediction of genotoxicity: room for improvement Drug Discovery Today 10, 1119-1124 10.1016/S1359-6446(05)03505-1
42. Snyder, R. D. (2010) Possible structural and functional determinants contributing to the clastogenicity of pharmaceuticals Environ. Mol. Mutagen. 51, 800-814 10.1002/em.20626
43. Sutter, A., Amberg, A., Boyer, S., Brigo, A., Contrera, J. F., Custer, L. L., Dobo, K. L., Gervais, V., Glowienke, S., van Gompel, J., Greene, N., Muster, W., Nicolette, J., Reddy, M. V., Thybaud, V., Vock, E., White, A. T., and Muller, L. (2013) Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities Regul. Toxicol. Pharmacol. 67, 39-52 10.1016/j.yrtph.2013.05.001
44. Chen, L., Li, Y., Yu, H., Zhang, L., and Hou, T. (2012) Computational models for predicting substrates or inhibitors of P-glycoprotein Drug Discovery Today 17, 343-351 10.1016/j.drudis.2011.11.003
45. Halliwell, W. H. (1997) Cationic amphiphilic drug-induced phospholipidosis Toxicol. Pathol. 25, 53-60 10.1177/019262339702500111
46. Reasor, M. J. and Kacew, S. (2001) Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. 226, 825-830
47. Pelletier, D. J., Gehlhaar, D., Tilloy-Ellul, A., Johnson, T. O., and Greene, N. (2007) Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential J. Chem. Inf. Model. 47, 1196-1205 10.1021/ci6004542
48. Ploemen, J. P., Kelder, J., Hafmans, T., van de SAndt, H., van Burgsteden, J. A., Saleminki, P. J., and van, E. E. (2004) Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines Exp. Toxicol. Pathol. 55, 347-355 10.1078/0940-2993-00338
49. Goracci, L., Ceccarelli, M., Bonelli, D., and Cruciani, G. (2013) Modeling phospholipidosis induction: reliability and warnings J. Chem. Inf. Model. 53, 1436-1446 10.1021/ci400113t
50. Hanumegowda, U. M., Wenke, G., Regueiro-Ren, A., Yordanova, R., Corradi, J. P., and Adams, S. P. (2010) Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds Chem. Res. Toxicol. 23, 749-755 10.1021/tx9003825
51. Choi, S. S., Kim, J. S., Valerio, L. G., Jr., and Sadrieh, N. (2013) In silico modeling to predict drug-induced phospholipidosis Toxicol. Appl. Pharmacol. 269, 195-204 10.1016/j.taap.2013.03.010
52. Vieth, M., Sutherland, J. J., Robertson, D. H., and Campbell, R. M. (2005) Kinomics: characterizing the therapeutically validated kinase space Drug Discovery Today 10, 839-846 10.1016/S1359-6446(05)03477-X
53. Metz, J. T. and Hajduk, P. J. (2010) Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks Curr. Opin. Chem. Biol. 14, 498-504 10.1016/j.cbpa.2010.06.166
54. Blomme, E. A., Yang, Y., and Waring, J. F. (2009) Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development Toxicol. Lett. 186, 22-31 10.1016/j.toxlet.2008.09.017
55. Rana, P., Anson, B., Engle, S., and Will, Y. (2012) Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening Toxicol. Sci. 130, 117-131 10.1093/toxsci/kfs233
56. Marroquin, L. D., Hynes, J., Dykens, J. A., Jamieson, J. D., and Will, Y. (2007) Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants Toxicol. Sci. 97, 539-547 10.1093/toxsci/kfm052
57. Ekwall, B., Barile, F. A., Castano, A., Clemedson, C., Clothier, R. H., Dierickx, P., Ekwall, B., Ferro, M., Fiskesjö, G., Garza-Ocañas, L., Gómez-Lechón, M. J., Gülden, M., Hall, T., Isomaa, B., Kahru, A., Kerszman, G., Kristen, U., Kunimoto, M., Kärenlampi, S., Lewan, L., Loukianov, A., Ohno, T., Persoone, G., Romert, L., Sawyer, T. W., Shrivastava, R., Segner, H., Stammati, A., Tanaka, N., Valentino, M., Walum, E., and Zucco, F. (1998) MEIC Evaluation of Acute Systemic Toxicity. Part VI. The Prediction of Human Toxicity by Rodent LD50 Values and Results From 61 In Vitro Methods ALTA 26, 617-658
58. Diehl, M. S., Willaby, S. L., and Snyder, R. D. (2000) Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays Environ. Mol. Mutagen. 36, 72-77 10.1002/1098-2280(2000)36:1<72::AID-EM10>3.0.CO;2-Y
59. Escobar, P. A., Kemper, R. A., Tarca, J., Nicolette, J., Kenyon, M., Glowienke, S., Sawant, S. G., Christensen, J., Johnson, T. E., McKnight, C., Ward, G., Galloway, S. M., Custer, L., Gocke, E., O'Donovan, M. R., Braun, K., Snyder, R. D., and Mahadevan, B. (2013) Bacterial mutagenicity screening in the pharmaceutical industry Mutat. Res., Rev. Mutat. Res. 752, 99-118 10.1016/j.mrrev.2012.12.002
60. Nicolette, J. and Blomme, E. (2011) Applications of Flow Cytometry in Genetic Toxicology Am. Drug Discovery 6, 52-55
61. Decordier, I., Papine, A., Plas, G., Roesems, S., Vande Loock, K., Moreno-Palomo, J., Cemeli, E., Anderson, D., Fucic, A., Marcos, R., Soussaline, F., and Kirsch-Volders, M. (2009) Automated image analysis of cytokinesis-blocked micronuclei: an adapted protocol and a validated scoring procedure for biomonitoring Mutagenesis 24, 85-93 10.1093/mutage/gen057
62. Nicolette, J., Diehl, M., Sonders, P., Bryce, S., and Blomme, E. (2011) In vitro micronucleus screening of pharmaceutical candidates by flow cytometry in Chinese hamster V79 cells Environ. Mol. Mutagen. 52, 355-362 10.1002/em.20631
63. Olaharski, A., Albertini, S., Kirchner, S., Platz, S., Uppal, H., Lin, H., and Kolaja, K. (2009) Evaluation of the GreenScreen GADD45alpha-GFP indicator assay with non-proprietary and proprietary compounds Mutat. Res., Genet. Toxicol. Environ. Mutagen. 672, 10-16 10.1016/j.mrgentox.2008.08.019
64. Walmsley, R. M. and Tate, M. (2012) The GADD45a-GFP GreenScreen HC assay Methods Mol. Biol. 817, 231-250 10.1007/978-1-61779-421-6-12
65. Luzy, A. P., Orsini, N., Linget, J. M., and Bouvier, G. (2013) Evaluation of the GADD45alpha-GFP GreenScreen HC assay for rapid and reliable in vitro early genotoxicity screening J. Appl. Toxicol. 33, 1303-1315 10.1002/jat.2793
66. Krishna, G., Fiedler, R., and Theiss, J. C. (1992) Simultaneous evaluation of clastogenicity, aneugenicity and toxicity in the mouse micronucleus assay using immunofluorescence Mutat. Res. Lett. 282, 159-167 10.1016/0165-7992(92)90090-5
67. Bryce, S. M., Shi, J., Nicolette, J., Diehl, M., Sonders, P., Avlasevich, S., Raja, S., Bemis, J. C., and Dertinger, S. D. (2010) High content flow cytometric micronucleus scoring method is applicable to attachment cell lines Environ. Mol. Mutagen. 51, 260-266 10.1002/em.20544
68. Peters, J. U., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., Migeon, J., Fischer, H., Guba, W., and Kansy, M. (2012) Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discovery Today 17, 325-335 10.1016/j.drudis.2012.01.001
69. Papoian, T., Chiu, H. J., Elayan, I., Jagadeesh, G., Khan, I., Laniyonu, A. A., Li, C. X., Saulnier, M., Simpson, N., and Yang, B. (2015) Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective Nat. Rev. Drug Discovery 14, 294 10.1038/nrd3845-c1
70. Mestres, J., Gregori-Puigjane, E., Valverde, S., and Sole, R. V. (2008) Data completeness - the Achilles heel of drug-target networks Nat. Biotechnol. 26, 983-984 10.1038/nbt0908-983
71. Whitebread, S., Hamon, J., Bojanic, D., and Urban, L. (2005) Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development Drug Discovery Today 10, 1421-1433 10.1016/S1359-6446(05)03632-9
72. Elangbam, C. S. (2010) Drug-induced valvulopathy: an update Toxicol. Pathol. 38, 837-848 10.1177/0192623310378027
73. Engle, S. K., Solter, P. F., Credille, K. M., Bull, C. M., Adams, S., Berna, M. J., Schultze, A. E., Rothstein, E. C., Cockman, M. D., Pritt, M. L., Liu, H., Lu, Y., Chiang, A. Y., and Watson, D. E. (2010) Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging Toxicol. Sci. 114, 183-192 10.1093/toxsci/kfp311
74. Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., and Whitebread, S. (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Nat. Rev. Drug Discovery 11, 909-922 10.1038/nrd3845
75. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome Science 298, 1912-1934 10.1126/science.1075762
76. Goldstein, D. M., Gray, N. S., and Zarrinkar, P. P. (2008) High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discovery 7, 391-397 10.1038/nrd2541
77. Paricharak, S., Klenka, T., Augustin, M., Patel, U. A., and Bender, A. (2013) Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases J. Cheminf. 5, 49 10.1186/1758-2946-5-49
78. Ferre, F., Palmeri, A., and Helmer-Citterich, M. (2014) Computational methods for analysis and inference of kinase/inhibitor relationships Front. Genet. 5, 196 10.3389/fgene.2014.00196
79. Bhargava, P. (2009) VEGF kinase inhibitors: how do they cause hypertension? Am. J. Physiol.: Regul., Integr. Comp. Physiol 297, R1-R5 10.1152/ajpregu.90502.2008
80. Shah, D. R., Shah, R. R., and Morganroth, J. (2013) Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy Drug Saf. 36, 413-426 10.1007/s40264-013-0050-x
81. Force, T. and Kolaja, K. L. (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat. Rev. Drug Discovery 10, 111-126 10.1038/nrd3252
82. Olaharski, A. J., Gonzaludo, N., Bitter, H., Goldstein, D., Kirchner, S., Uppal, H., and Kolaja, K. (2009) Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors PLoS Comput. Biol. 5, e1000446 10.1371/journal.pcbi.1000446
83. Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F., and Gintant, G. A. (2004) The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block J. Cardiovasc. Pharmacol. 43, 369-379 10.1097/00005344-200403000-00007
84. Rampe, D. and Brown, A. M. (2013) A history of the role of the hERG channel in cardiac risk assessment J. Pharmacol. Toxicol. Methods 68, 13-22 10.1016/j.vascn.2013.03.005
85. Park, E., Willard, J., Bi, D., Fiszman, M., Kozeli, D., and Koerner, J. (2013) The impact of drug-related QT prolongation on FDA regulatory decisions Int. J. Cardiol. 168, 4975-4976 10.1016/j.ijcard.2013.07.136
86. Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C., and January, C. T. (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels Circ. Res. 84, 989-998 10.1161/01.RES.84.9.989
87. Meyer, T., Boven, K. H., Gunther, E., and Fejtl, M. (2004) Micro-electrode arrays in cardiac safety pharmacology: a novel tool to study QT interval prolongation Drug Saf. 27, 763-772 10.2165/00002018-200427110-00002
88. Beacham, D. W., Blackmer, T., O'Grady, M., and Hanson, G. T. (2010) Cell-based potassium ion channel screening using the FluxOR assay J. Biomol. Screening 15, 441-446 10.1177/1087057109359807
89. Kramer, J., Obejero-Paz, C. A., Myatt, G., Kuryshev, Y. A., Bruening-Wright, A., Verducci, J. S., and Brown, A. M. (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes Sci. Rep. 3, 2100 10.1038/srep02100
90. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. (2014) Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium Am. Heart J. 167, 292-300 10.1016/j.ahj.2013.11.004
91. Williams, G. and Mirams, G. R. (2015) A web portal for in-silico action potential predictions J. Pharmacol. Toxicol. Methods 75, 10-16 10.1016/j.vascn.2015.05.002
92. Peters, M. F., Lamore, S. D., Guo, L., Scott, C. W., and Kolaja, K. L. (2015) Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line Cardiovasc. Toxicol. 15, 127-139 10.1007/s12012-014-9268-9
93. Asakura, K., Hayashi, S., Ojima, A., Taniguchi, T., Miyamoto, N., Nakamori, C., Nagasawa, C., Kitamura, T., Osada, T., Honda, Y., Kasai, C., Ando, H., Kanda, Y., Sekino, Y., and Sawada, K. (2015) Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes J. Pharmacol. Toxicol. Methods 75, 17-26 10.1016/j.vascn.2015.04.002
94. Guo, L., Coyle, L., Abrams, R. M., Kemper, R., Chiao, E. T., and Kolaja, K. L. (2013) Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model Toxicol. Sci. 136, 581-594 10.1093/toxsci/kft205
95. Himmel, H. M. (2013) Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds J. Pharmacol. Toxicol. Methods 68, 97-111 10.1016/j.vascn.2013.05.005
96. Robertson, C., Tran, D. D., and George, S. C. (2013) Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes Stem Cells 31, 829-837 10.1002/stem.1331
97. Martins, A. M., Vunjak-Novakovic, G., and Reis, R. L. (2014) The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine Stem Cell Rev. 10, 177-190 10.1007/s12015-013-9487-7
98. Xu, J. J., Diaz, D., and O'Brien, P. J. (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential Chem.-Biol. Interact. 150, 115-128 10.1016/j.cbi.2004.09.011
99. Tolosa, L., Gomez-Lechon, M. J., and Donato, M. T. (2015) High-content screening technology for studying drug-induced hepatotoxicity in cell models Arch. Toxicol. 89, 1007-1022 10.1007/s00204-015-1503-z
100. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., Brain, P., and Hougham, C. (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening Arch. Toxicol. 80, 580-604 10.1007/s00204-006-0091-3
101. Abraham, V. C., Towne, D. L., Waring, J. F., Warrior, U., and Burns, D. J. (2008) Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans J. Biomol. Screening 13, 527-537 10.1177/1087057108318428
102. Benbow, J. W., Aubrecht, J., Banker, M. J., Nettleton, D., and Aleo, M. D. (2010) Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies Toxicol. Lett. 197, 175-182 10.1016/j.toxlet.2010.05.016
103. Greene, N., Aleo, M. D., Louise-May, S., Price, D. A., and Will, Y. (2010) Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies Bioorg. Med. Chem. Lett. 20, 5308-5312 10.1016/j.bmcl.2010.06.129
104. Shah, F., Louise-May, S., and Greene, N. (2014) Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG2 cell lines Bioorg. Med. Chem. Lett. 24, 2753-2757 10.1016/j.bmcl.2014.04.039
105. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002) Effects of troglitazone on HepG2 viability and mitochondrial function Toxicol. Sci. 69, 131-138 10.1093/toxsci/69.1.131
106. Westwood, F. R., Bigley, A., Randall, K., Marsden, A. M., and Scott, R. C. (2005) Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity Toxicol. Pathol. 33, 246-257 10.1080/01926230590908213
107. Porceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., and Borgne-Sanchez, A. (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria Toxicol. Sci. 129, 332-345 10.1093/toxsci/KFS197
108. Pessayre, D., Fromenty, B., Berson, A., Robin, M. A., Letteron, P., Moreau, R., and Mansouri, A. (2012) Central role of mitochondria in drug-induced liver injury Drug Metab. Rev. 44, 34-87 10.3109/03602532.2011.604086
109. Boelsterli, U. A. and Lim, P. L. (2007) Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220, 92-107 10.1016/j.taap.2006.12.013
110. Haasio, K., Nissinen, E., Sopanen, L., and Heinonen, E. H. (2002) Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects J. Neural Transm. 109, 1391-1401 10.1007/s00702-002-0748-x
111. Nadanaciva, S., Rana, P., Beeson, G. C., Chen, D., Ferrick, D. A., Beeson, C. C., and Will, Y. (2012) Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform J. Bioenerg. Biomembr. 44, 421-437 10.1007/s10863-012-9446-z
112. Nadanaciva, S., Willis, J. H., Barker, M. L., Gharaibeh, D., Capaldi, R. A., Marusich, M. F., and Will, Y. (2009) Lateral-flow immunoassay for detecting drug-induced inhibition of mitochondrial DNA replication and mtDNA-encoded protein synthesis J. Immunol. Methods 343, 1-12 10.1016/j.jim.2008.12.002
113. Selvaraj, S., Ghebremichael, M., Li, M., Foli, Y., Langs-Barlow, A., Ogbuagu, A., Barakat, L., Tubridy, E., Edifor, R., Lam, W., Cheng, Y. C., and Paintsil, E. (2014) Antiretroviral therapy-induced mitochondrial toxicity: potential mechanisms beyond polymerase-gamma inhibition Clin. Pharmacol. Ther. 96, 110-120 10.1038/clpt.2014.64
114. Nadanaciva, S., Dykens, J. A., Bernal, A., Capaldi, R. A., and Will, Y. (2007) Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration Toxicol. Appl. Pharmacol. 223, 277-287 10.1016/j.taap.2007.06.003
115. Will, Y. and Dykens, J. (2014) Mitochondrial toxicity assessment in industry - a decade of technology development and insight Expert Opin. Drug Metab. Toxicol. 10, 1061-1067 10.1517/17425255.2014.939628
116. Swiss, R., Niles, A., Cali, J. J., Nadanaciva, S., and Will, Y. (2013) Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death Toxicol. In Vitro 27, 1789-1797 10.1016/j.tiv.2013.05.007
117. Hynes, J., Nadanaciva, S., Swiss, R., Carey, C., Kirwan, S., and Will, Y. (2013) A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays Toxicol. In Vitro 27, 560-569 10.1016/j.tiv.2012.11.002
118. Mehta, R., Chan, K., Lee, O., Tafazoli, S., and O'Brien, P. (2008) Drug-Associated Mitochondrial Toxicity, in Drug-Induced Mitochondrial Dysfunction (Dykens, J. and Will, Y., Eds.) pp 71-126, John Wiley & Sons, Inc., New York.
119. Divakaruni, A. S., Rogers, G. W., and Murphy, A. N. (2014) Measuring Mitochondrial Function in Permeabilized Cells Using the Seahorse XF Analyzer or a Clark-Type Oxygen Electrode Curr. Protoc. Toxicol 60, 25.2.1-25.2.16 10.1002/0471140856.tx2502s60
120. Rogers, G. W., Nadanaciva, S., Swiss, R., Divakaruni, A. S., and Will, Y. (2014) Assessment of Fatty Acid Beta oxidation in cells and isolated mitochondria Curr. Protoc. Toxicol 60, 25.3.1-25.3.19 10.1002/0471140856.tx2503s60
121. Dykens, J. A., Jamieson, J., Marroquin, L., Nadanaciva, S., Billis, P. A., and Will, Y. (2008) Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro Toxicol. Appl. Pharmacol. 233, 203-210 10.1016/j.taap.2008.08.013
122. Dykens, J. A., Jamieson, J. D., Marroquin, L. D., Nadanaciva, S., Xu, J. J., Dunn, M. C., Smith, A. R., and Will, Y. (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone Toxicol. Sci. 103, 335-345 10.1093/toxsci/kfn056
123. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008) Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105, 97-105 10.1093/toxsci/kfn109
124. Kostrubsky, S. E., Strom, S. C., Kalgutkar, A. S., Kulkarni, S., Atherton, J., Mireles, R., Feng, B., Kubik, R., Hanson, J., Urda, E., and Mutlib, A. E. (2006) Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone Toxicol. Sci. 90, 451-459 10.1093/toxsci/kfj095
125. Aleo, M. D., Luo, Y., Swiss, R., Bonin, P. D., Potter, D. M., and Will, Y. (2014) Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump Hepatology 60, 1015-1022 10.1002/hep.27206
126. Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, B., Stahl, S., Foster, A. J., Dolgos, H., Weaver, R., and Kenna, J. G. (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs Chem. Res. Toxicol. 25, 1616-1632 10.1021/tx300091x
127. Kenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., and Thompson, R. A. (2015) Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists J. Pharmacol. Exp. Ther. 352, 281-90 10.1124/jpet.114.220491
128. Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., and Aleo, M. D. (2015) Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays Toxicol. Sci. 147, 500-514 10.1093/toxsci/kfv152
129. Meng, Q. (2010) Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity Expert Opin. Drug Metab. Toxicol. 6, 733-746 10.1517/17425251003674356
130. Messner, S., Agarkova, I., Moritz, W., and Kelm, J. M. (2013) Multi-cell type human liver microtissues for hepatotoxicity testing Arch. Toxicol. 87, 209-213 10.1007/s00204-012-0968-2
131. Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Bottger, J., Braeuning, A., Budinsky, R. A., Burkhardt, B., Cameron, N. R., Camussi, G., Cho, C. S., Choi, Y. J., Craig, R. J., Dahmen, U., Damm, G., Dirsch, O., Donato, M. T., Dong, J., Dooley, S., Drasdo, D., Eakins, R., Ferreira, K. S., Fonsato, V., Fraczek, J., Gebhardt, R., Gibson, A., Glanemann, M., Goldring, C. E., Gomez-Lechon, M. J., Groothuis, G. M., Gustavsson, L., Guyot, C., Hallifax, D., Hammad, S., Hayward, A., Haussinger, D., Hellerbrand, C., Hewitt, P., Hoehme, S., Holzhutter, H. G., Houston, J. B., Hrach, J., Ito, K., Jaeschke, H., Keitel, V., Kelm, J. M., Kevin, P. B., Kordes, C., Kullak-Ublick, G. A., LeCluyse, E. L., Lu, P., Luebke-Wheeler, J., Lutz, A., Maltman, D. J., Matz-Soja, M., McMullen, P., Merfort, I., Messner, S., Meyer, C., Mwinyi, J., Naisbitt, D. J., Nussler, A. K., Olinga, P., Pampaloni, F., Pi, J., Pluta, L., Przyborski, S. A., Ramachandran, A., Rogiers, V., Rowe, C., Schelcher, C., Schmich, K., Schwarz, M., Singh, B., Stelzer, E. H., Stieger, B., Stober, R., Sugiyama, Y., Tetta, C., Thasler, W. E., Vanhaecke, T., Vinken, M., Weiss, T. S., Widera, A., Woods, C. G., Xu, J. J., Yarborough, K. M., and Hengstler, J. G. (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME Arch. Toxicol. 87, 1315-1530 10.1007/s00204-013-1078-5
132. Takahashi, Y., Hori, Y., Yamamoto, T., Urashima, T., Ohara, Y., and Tanaka, H. 3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells. Biosci. Rep. 2015, in press
133. Ditewig, A. C., Cugier, D. J., Liguori, M. J., Yang, Y., and Blomme, E. A. (2013) Transcriptomic evaluation of canine suspension-shipped and pre-plated hepatocytes: comparison to liver Toxicol. Mech. Methods 23, 479-490 10.3109/15376516.2013.796031
134. Persson, M., Loye, A. F., Mow, T., and Hornberg, J. J. (2013) A high content screening assay to predict human drug-induced liver injury during drug discovery J. Pharmacol. Toxicol. Methods 68, 302-313 10.1016/j.vascn.2013.08.001
135. Hornberg, J. J., Laursen, M., Brenden, N., Persson, M., Thougaard, A. V., Toft, D. B., and Mow, T. (2014) Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies Drug Discovery Today 19, 1137-1144 10.1016/j.drudis.2013.12.009
136. Chandra, P. and Brouwer, K. L. (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts Pharm. Res. 21, 719-735 10.1023/B:PHAM.0000026420.79421.8f
137. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans Drug Metab. Dispos. 40, 130-138 10.1124/dmd.111.040758
138. Yang, Y., Abel, S. J., Ciurlionis, R., and Waring, J. F. (2006) Development of a toxicogenomics in vitro assay for the efficient characterization of compounds Pharmacogenomics 7, 177-186 10.2217/14622416.7.2.177
139. Sawada, H., Takami, K., and Asahi, S. (2005) A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system Toxicol. Sci. 83, 282-292 10.1093/toxsci/kfh264
140. Atienzar, F., Gerets, H., Dufrane, S., Tilmant, K., Cornet, M., Dhalluin, S., Ruty, B., Rose, G., and Canning, M. (2007) Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells Toxicol. Sci. 96, 101-114 10.1093/toxsci/kfl184
141. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 10, 292-306 10.1038/nrd3408
142. Hussaini, S. H. and Farrington, E. A. (2014) Idiosyncratic drug-induced liver injury: an update on the 2007 overview Expert Opin. Drug Saf. 13, 67-81 10.1517/14740338.2013.828032
143. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., and Okazaki, O. (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37, 1970-1977 10.1124/dmd.109.027797
144. Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., Collins, J. E., Humphray, S., McLaren, K., Matthews, L., McLaren, S., Sealy, I., Caccamo, M., Churcher, C., Scott, C., Barrett, J. C., Koch, R., Rauch, G. J., White, S., Chow, W., Kilian, B., Quintais, L. T., Guerra-Assuncao, J. A., Zhou, Y., Gu, Y., Yen, J., Vogel, J. H., Eyre, T., Redmond, S., Banerjee, R., Chi, J., Fu, B., Langley, E., Maguire, S. F., Laird, G. K., Lloyd, D., Kenyon, E., Donaldson, S., Sehra, H., meida-King, J., Loveland, J., Trevanion, S., Jones, M., Quail, M., Willey, D., Hunt, A., Burton, J., Sims, S., McLay, K., Plumb, B., Davis, J., Clee, C., Oliver, K., Clark, R., Riddle, C., Elliot, D., Threadgold, G., Harden, G., Ware, D., Begum, S., Mortimore, B., Kerry, G., Heath, P., Phillimore, B., Tracey, A., Corby, N., Dunn, M., Johnson, C., Wood, J., Clark, S., Pelan, S., Griffiths, G., Smith, M., Glithero, R., Howden, P., Barker, N., Lloyd, C., Stevens, C., Harley, J., Holt, K., Panagiotidis, G., Lovell, J., Beasley, H., Henderson, C., Gordon, D., Auger, K., Wright, D., Collins, J., Raisen, C., Dyer, L., Leung, K., Robertson, L., Ambridge, K., Leongamornlert, D., McGuire, S., Gilderthorp, R., Griffiths, C., Manthravadi, D., Nichol, S., Barker, G., Whitehead, S., Kay, M., Brown, J., Murnane, C., Gray, E., Humphries, M., Sycamore, N., Barker, D., Saunders, D., Wallis, J., Babbage, A., Hammond, S., Mashreghi-Mohammadi, M., Barr, L., Martin, S., Wray, P., Ellington, A., Matthews, N., Ellwood, M., Woodmansey, R., Clark, G., Cooper, J., Tromans, A., Grafham, D., Skuce, C., Pandian, R., Andrews, R., Harrison, E., Kimberley, A., Garnett, J., Fosker, N., Hall, R., Garner, P., Kelly, D., Bird, C., Palmer, S., Gehring, I., Berger, A., Dooley, C. M., Ersan-Urun, Z., Eser, C., Geiger, H., Geisler, M., Karotki, L., Kirn, A., Konantz, J., Konantz, M., Oberlander, M., Rudolph-Geiger, S., Teucke, M., Lanz, C., Raddatz, G., Osoegawa, K., Zhu, B., Rapp, A., Widaa, S., Langford, C., Yang, F., Schuster, S. C., Carter, N. P., Harrow, J., Ning, Z., Herrero, J., Searle, S. M., Enright, A., Geisler, R., Plasterk, R. H., Lee, C., Westerfield, M., de Jong, P. J., Zon, L. I., Postlethwait, J. H., Nusslein-Volhard, C., Hubbard, T. J., Roest, C. H., Rogers, J., and Stemple, D. L. (2013) The zebrafish reference genome sequence and its relationship to the human genome Nature 496, 498-503 10.1038/nature12111
145. Chapin, R., Augustine-Rauch, K., Beyer, B., Daston, G., Finnell, R., Flynn, T., Hunter, S., Mirkes, P., O'Shea, K. S., Piersma, A., Sandler, D., Vanparys, P., and Van Maele-Fabry, G. (2008) State of the art in developmental toxicity screening methods and a way forward: a meeting report addressing embryonic stem cells, whole embryo culture, and zebrafish Birth Defects Res., Part B 83, 446-456 10.1002/bdrb.20158
146. Mesens, N., Crawford, A. D., Menke, A., Hung, P. D., Van Goethem, F., Nuyts, R., Hansen, E., Wolterbeek, A., van Gompel, J., De Witte, P., and Esguerra, C. V. (2015) Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates? J. Appl. Toxicol. 35, 1017-1029 10.1002/jat.3091
147. Driessen, M., Vitins, A. P., Pennings, J. L., Kienhuis, A. S., Water, B., and van der Ven, L. T. M. (2015) A transcriptomics-based hepatotoxicity comparison between the zebrafish embryo and established human and rodent in vitro and in vivo models using cyclosporine A, amiodarone and acetaminophen Toxicol. Lett. 232, 403-412 10.1016/j.toxlet.2014.11.020
148. Milan, D. J., Peterson, T. A., Ruskin, J. N., Peterson, R. T., and MacRae, C. A. (2003) Drugs that induce repolarization abnormalities cause bradycardia in zebrafish Circulation 107, 1355-1358 10.1161/01.CIR.0000061912.88753.87
149. Berghmans, S., Butler, P., Goldsmith, P., Waldron, G., Gardner, I., Golder, Z., Richards, F. M., Kimber, G., Roach, A., Alderton, W., and Fleming, A. (2008) Zebrafish based assays for the assessment of cardiac, visual and gut function - potential safety screens for early drug discovery J. Pharmacol. Toxicol. Methods 58, 59-68 10.1016/j.vascn.2008.05.130
150. Mittelstadt, S. W., Hemenway, C. L., Craig, M. P., and Hove, J. R. (2008) Evaluation of zebrafish embryos as a model for assessing inhibition of hERG J. Pharmacol. Toxicol. Methods 57, 100-105 10.1016/j.vascn.2007.10.004
151. Tsutsui, H., Higashijima, S., Miyawaki, A., and Okamura, Y. (2010) Visualizing voltage dynamics in zebrafish heart J. Physiol. 588, 2017-2021 10.1113/jphysiol.2010.189126
152. Chan, P. K., Lin, C. C., and Cheng, S. H. (2009) Noninvasive technique for measurement of heartbeat regularity in zebrafish (Danio rerio) embryos BMC Biotechnol. 9, 11 10.1186/1472-6750-9-11
153. Han, Y., Zhang, J. P., Qian, J. Q., and Hu, C. Q. (2015) Cardiotoxicity evaluation of anthracyclines in zebrafish (Danio rerio) J. Appl. Toxicol. 35, 241-252 10.1002/jat.3007
154. Zhu, J. J., Xu, Y. Q., He, J. H., Yu, H. P., Huang, C. J., Gao, J. M., Dong, Q. X., Xuan, Y. X., and Li, C. Q. (2014) Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish J. Appl. Toxicol. 34, 139-148 10.1002/jat.2843
155. Koseki, N., Deguchi, J., Yamashita, A., Miyawaki, I., and Funabashi, H. (2014) Establishment of a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish J. Toxicol. Sci. 39, 579-600 10.2131/jts.39.579
156. Deeti, S., O'Farrell, S., and Kennedy, B. N. (2014) Early safety assessment of human oculotoxic drugs using the zebrafish visualmotor response J. Pharmacol. Toxicol. Methods 69, 1-8 10.1016/j.vascn.2013.09.002
157. Cassar, S., Huang, X., and Cole, T. (2015) A high-throughput method for predicting drug effects on gut transit time using larval zebrafish J. Pharmacol. Toxicol. Methods 76, 72-75 10.1016/j.vascn.2015.08.156
158. Bass, A. S., Cartwright, M. E., Mahon, C., Morrison, R., Snyder, R., McNamara, P., Bradley, P., Zhou, Y. Y., and Hunter, J. (2009) Exploratory drug safety: a discovery strategy to reduce attrition in development J. Pharmacol. Toxicol. Methods 60, 69-78 10.1016/j.vascn.2009.04.194
159. Roberts, R. A., Kavanagh, S. L., Mellor, H. R., Pollard, C. E., Robinson, S., and Platz, S. J. (2014) Reducing attrition in drug development: smart loading preclinical safety assessment Drug Discovery Today 19, 341-347 10.1016/j.drudis.2013.11.014
160. Pugsley, M. K., Authier, S., Stonerook, M., and Curtis, M. J. (2015) The shifting landscape of safety pharmacology in 2015 J. Pharmacol. Toxicol. Methods 75, 5-9 10.1016/j.vascn.2015.05.013
161. Hamdam, J., Sethu, S., Smith, T., Alfirevic, A., Alhaidari, M., Atkinson, J., Ayala, M., Box, H., Cross, M., Delaunois, A., Dermody, A., Govindappa, K., Guillon, J. M., Jenkins, R., Kenna, G., Lemmer, B., Meecham, K., Olayanju, A., Pestel, S., Rothfuss, A., Sidaway, J., Sison-Young, R., Smith, E., Stebbings, R., Tingle, Y., Valentin, J. P., Williams, A., Williams, D., Park, K., and Goldring, C. (2013) Safety pharmacology - current and emerging concepts Toxicol. Appl. Pharmacol. 273, 229-241 10.1016/j.taap.2013.04.039
162. Van Deuren, B., Van Ammel, K., Somers, Y., Cools, F., Straetemans, R., van der Linde, H. J., and Gallacher, D. J. (2009) The fentanyl/etomidate-anaesthetised beagle (FEAB) dog: a versatile in vivo model in cardiovascular safety research J. Pharmacol. Toxicol. Methods 60, 11-23 10.1016/j.vascn.2009.04.195
163. Hanson, L. A., Bass, A. S., Gintant, G., Mittelstadt, S., Rampe, D., and Thomas, K. (2006) ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation J. Pharmacol. Toxicol. Methods 54, 116-129 10.1016/j.vascn.2006.05.001
164. Derakhchan, K., Chui, R. W., Stevens, D., Gu, W., and Vargas, H. M. (2014) Detection of QTc interval prolongation using jacket telemetry in conscious non-human primates: comparison with implanted telemetry Br. J. Pharmacol. 171, 509-522 10.1111/bph.12484
165. Chui, R. W., Fosdick, A., Conner, R., Jiang, J., Bruenner, B. A., and Vargas, H. M. (2009) Assessment of two external telemetry systems (PhysioJacket and JET) in beagle dogs with telemetry implants J. Pharmacol. Toxicol. Methods 60, 58-68 10.1016/j.vascn.2009.04.196
166. Authier, S., Vargas, H. M., Curtis, M. J., Holbrook, M., and Pugsley, M. K. (2013) Safety pharmacology investigations in toxicology studies: an industry survey J. Pharmacol. Toxicol. Methods 68, 44-51 10.1016/j.vascn.2013.05.002
167. Thybaud, V., Dean, S., Nohmi, T., de Boer, J., Douglas, G. R., Glickman, B. W., Gorelick, N. J., Heddle, J. A., Heflich, R. H., Lambert, I., Martus, H. J., Mirsalis, J. C., Suzuki, T., and Yajima, N. (2003) In vivo transgenic mutation assays Mutat. Res., Genet. Toxicol. Environ. Mutagen. 540, 141-151 10.1016/j.mrgentox.2003.07.004
168. Dobrovolsky, V. N., Cao, X., Bhalli, J. A., and Heflich, R. H. (2014) Detection of Pig-a mutant erythrocytes in the peripheral blood of rats and mice Methods Mol. Biol. 1105, 205-221 10.1007/978-1-62703-739-6-17
169. Gollapudi, B. B., Lynch, A. M., Heflich, R. H., Dertinger, S. D., Dobrovolsky, V. N., Froetschl, R., Horibata, K., Kenyon, M. O., Kimoto, T., Lovell, D. P., Stankowski, L. F., Jr., White, P. A., Witt, K. L., and Tanir, J. Y. (2015) The in vivo Pig-a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup Mutat. Res., Genet. Toxicol. Environ. Mutagen. 783, 23-35 10.1016/j.mrgentox.2014.09.007
170. Morgan, S. J., Elangbam, C. S., Berens, S., Janovitz, E., Vitsky, A., Zabka, T., and Conour, L. (2013) Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals Toxicol. Pathol. 41, 508-518 10.1177/0192623312457273
171. Yang, Y., Dahly-Vernon, A. J., Blomme, E. A., Lai-Zhang, J., Kempf, D. J., Marsh, K. C., Harrington, Y. A., Nye, S. H., Evans, D. L., Roman, R. J., Jacob, H. J., and Waring, J. F. (2010) Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats Vet. J. 185, 75-82 10.1016/j.tvjl.2010.04.017
172. Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., and Harris, S. C. (2006) Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial JAMA 296, 87-93 10.1001/jama.296.1.87
173. Harrill, A. H., Ross, P. K., Gatti, D. M., Threadgill, D. W., and Rusyn, I. (2009) Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel Toxicol. Sci. 110, 235-243 10.1093/toxsci/kfp096
174. Howell, B. A., Yang, Y., Kumar, R., Woodhead, J. L., Harrill, A. H., Clewell, H. J., III, Andersen, M. E., Siler, S. Q., and Watkins, P. B. (2012) In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: a mechanistic, mathematical model of DILI J. Pharmacokinet. Pharmacodyn. 39, 527-541 10.1007/s10928-012-9266-0
175. Harrill, A. H., Watkins, P. B., Su, S., Ross, P. K., Harbourt, D. E., Stylianou, I. M., Boorman, G. A., Russo, M. W., Sackler, R. S., Harris, S. C., Smith, P. C., Tennant, R., Bogue, M., Paigen, K., Harris, C., Contractor, T., Wiltshire, T., Rusyn, I., and Threadgill, D. W. (2009) Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Genome Res. 19, 1507-1515 10.1101/gr.090241.108
176. Court, M. H., Peter, I., Hazarika, S., Vasiadi, M., Greenblatt, D. J., Lee, W. M., and Acute Liver Failure Study, G. (2014) Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure Drug Metab. Dispos. 42, 28-32 10.1124/dmd.113.053546
177. Dieterle, F., Sistare, F., Goodsaid, F., Papaluca, M., Ozer, J. S., Webb, C. P., Baer, W., Senagore, A., Schipper, M. J., Vonderscher, J., aaSultana, S., Gerhold, D. L., Phillips, J. A., Maurer, G., Carl, K., Laurie, D., Harpur, E., Sonee, M., Ennulat, D., Holder, D., ndrews-Cleavenger, D., Gu, Y. Z., Thompson, K. L., Goering, P. L., Vidal, J. M., Abadie, E., Maciulaitis, R., Jacobson-Kram, D., Defelice, A. F., Hausner, E. A., Blank, M., Thompson, A., Harlow, P., Throckmorton, D., Xiao, S., Xu, N., Taylor, W., Vamvakas, S., Flamion, B., Lima, B. S., Kasper, P., Pasanen, M., Prasad, K., Troth, S., Bounous, D., Robinson-Gravatt, D., Betton, G., Davis, M. A., Akunda, J., McDuffie, J. E., Suter, L., Obert, L., Guffroy, M., Pinches, M., Jayadev, S., Blomme, E. A., Beushausen, S. A., Barlow, V. G., Collins, N., Waring, J., Honor, D., Snook, S., Lee, J., Rossi, P., Walker, E., and Mattes, W. (2010) Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat. Biotechnol. 28, 455-462 10.1038/nbt.1625
178. Blomme, E. A. (2011) Assessing renal function: some significant improvements on the horizon Vet. J. 188, 128-129 10.1016/j.tvjl.2010.07.014
179. Mikaelian, I., Scicchitano, M., Mendes, O., Thomas, R. A., and Leroy, B. E. (2013) Frontiers in preclinical safety biomarkers: microRNAs and messenger RNAs Toxicol. Pathol. 41, 18-31 10.1177/0192623312448939
180. Sharapova, T., Devanarayan, V., LeRoy, B., Liguori, M. J., Blomme, E., Buck, W., and Maher, J. (2015) Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies Vet. Pathol. 10.1177/0300985815591076
181. Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., and Galas, D. J. (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury Proc. Natl. Acad. Sci. U. S. A. 106, 4402-4407 10.1073/pnas.0813371106
182. Clarke, J. D., Sharapova, T., Lake, A. D., Blomme, E., Maher, J., and Cherrington, N. J. (2014) Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis J. Appl. Toxicol. 34, 726-732 10.1002/jat.2960
183. Khan, S. R., Baghdasarian, A., Fahlman, R. P., Michail, K., and Siraki, A. G. (2014) Current status and future prospects of toxicogenomics in drug discovery Drug Discovery Today 19, 562-578 10.1016/j.drudis.2013.11.001
184. Fielden, M. R., Nie, A., McMillian, M., Elangbam, C. S., Trela, B. A., Yang, Y., Dunn, R. T., Dragan, Y., Fransson-Stehen, R., Bogdanffy, M., Adams, S. P., Foster, W. R., Chen, S. J., Rossi, P., Kasper, P., Jacobson-Kram, D., Tatsuoka, K. S., Wier, P. J., Gollub, J., Halbert, D. N., Roter, A., Young, J. K., Sina, J. F., Marlowe, J., Martus, H. J., Aubrecht, J., Olaharski, A. J., Roome, N., Nioi, P., Pardo, I., Snyder, R., Perry, R., Lord, P., Mattes, W., and Car, B. D. (2008) Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat Toxicol. Sci. 103, 28-34 10.1093/toxsci/kfn022
185. Yang, Y., Ciurlionis, R., Kowalkowski, K., Marsh, K. C., Bracken, W. M., and Blomme, E. A. (2012) N-vinylpyrrolidone dimer, a novel formulation excipient, causes hepatic and thyroid hypertrophy through the induction of hepatic microsomal enzymes in rats Toxicol. Lett. 208, 82-91 10.1016/j.toxlet.2011.10.012
186. Laifenfeld, D., Qiu, L., Swiss, R., Park, J., Macoritto, M., Will, Y., Younis, H. S., and Lawton, M. (2014) Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury Toxicol. Sci. 137, 234-248 10.1093/toxsci/kft232
187. Fielden, M. R., Eynon, B. P., Natsoulis, G., Jarnagin, K., Banas, D., and Kolaja, K. L. (2005) A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity Toxicol. Pathol. 33, 675-683 10.1080/01926230500321213
188. Blomme, E. A., Ciurlionis, R., Marsh, K. C., Waring, J. F., and Yang, Y. (2008) Evaluation of the effects of serial phlebotomy on the transcriptome of major tissues and on the response to toxicants in rats Toxicol. Lett. 176, 138-148 10.1016/j.toxlet.2007.09.014
189. Gu, Y. G., Weitzberg, M., Clark, R. F., Xu, X., Li, Q., Lubbers, N. L., Yang, Y., Beno, D. W., Widomski, D. L., Zhang, T., Hansen, T. M., Keyes, R. F., Waring, J. F., Carroll, S. L., Wang, X., Wang, R., Healan-Greenberg, C. H., Blomme, E. A., Beutel, B. A., Sham, H. L., and Camp, H. S. (2007) N-(3-2-(4-alkoxyphenoxy)thiazol-5-yl-1-methylprop-2-ynyl)carboxy derivatives as acetyl-coA carboxylase inhibitors - improvement of cardiovascular and neurological liabilities via structural modifications J. Med. Chem. 50, 1078-1082 10.1021/jm070035a
190. Fricano, M. M., Ditewig, A. C., Jung, P. M., Liguori, M. J., Blomme, E. A., and Yang, Y. (2011) Global transcriptomic profiling using small volumes of whole blood: a cost-effective method for translational genomic biomarker identification in small animals Int. J. Mol. Sci. 12, 2502-2517 10.3390/ijms12042502
191. Nishimura, Y., Morikawa, Y., Kondo, C., Tonomura, Y., Fukushima, R., Torii, M., and Uehara, T. (2013) Genomic biomarkers for cardiotoxicity in rats as a sensitive tool in preclinical studies J. Appl. Toxicol. 33, 1120-1130 10.1002/jat.2867
192. Semizarov, D. and Blomme, E. (2008) Genomics in Drug Discovery and Development, John Wiley and Sons, Inc., Hoboken, NJ.
193. Kramer, J. A., Curtiss, S. W., Kolaja, K. L., Alden, C. L., Blomme, E. A., Curtiss, W. C., Davila, J. C., Jackson, C. J., and Bunch, R. T. (2004) Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling Chem. Res. Toxicol. 17, 463-470 10.1021/tx034244j
194. Ellinger-Ziegelbauer, H., Stuart, B., Wahle, B., Bomann, W., and Ahr, H. J. (2005) Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver Mutat. Res., Fundam. Mol. Mech. Mutagen. 575, 61-84 10.1016/j.mrfmmm.2005.02.004
195. Buck, W. R., Waring, J. F., and Blomme, E. A. (2008) Use of traditional end points and gene dysregulation to understand mechanisms of toxicity: toxicogenomics in mechanistic toxicology Methods Mol. Biol. 460, 23-44 10.1007/978-1-60327-048-9-2
196. Waring, J. F., Yang, Y., Healan-Greenberg, C. H., Adler, A. L., Dickinson, R., McNally, T., Wang, X., Weitzberg, M., Xu, X., Lisowski, A., Warder, S. E., Gu, Y. G., Zinker, B. A., Blomme, E. A., and Camp, H. S. (2008) Gene expression analysis in rats treated with experimental acetyl-coenzyme A carboxylase inhibitors suggests interactions with the peroxisome proliferator-activated receptor alpha pathway J. Pharmacol. Exp. Ther. 324, 507-516 10.1124/jpet.107.126938
197. Gomez-Lechon, M. J., Donato, M. T., Castell, J. V., and Jover, R. (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism Curr. Drug Metab. 4, 292-312 10.2174/1389200033489424
198. Schyschka, L., Sanchez, J. J., Wang, Z., Burkhardt, B., Muller-Vieira, U., Zeilinger, K., Bachmann, A., Nadalin, S., Damm, G., and Nussler, A. K. (2013) Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity Arch. Toxicol. 87, 1581-1593 10.1007/s00204-013-1080-y
199. Tostoes, R. M., Leite, S. B., Miranda, J. P., Sousa, M., Wang, D. I., Carrondo, M. J., and Alves, P. M. (2011) Perfusion of 3D encapsulated hepatocytes - a synergistic effect enhancing long-term functionality in bioreactors Biotechnol. Bioeng. 108, 41-49 10.1002/bit.22920
200. Gomez-Lechon, M. J., Tolosa, L., Conde, I., and Donato, M. T. (2014) Competency of different cell models to predict human hepatotoxic drugs Expert Opin. Drug Metab. Toxicol. 10, 1553-1568 10.1517/17425255.2014.967680
201. Gunness, P., Mueller, D., Shevchenko, V., Heinzle, E., Ingelman-Sundberg, M., and Noor, F. (2013) 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies Toxicol. Sci. 133, 67-78 10.1093/toxsci/kft021
202. Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., and Rusyn, I. (2013) models for liver toxicity testing Toxicol. Res. 2, 23-39 10.1039/C2TX20051A
203. van Zijl, F. and Mikulits, W. (2010) Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver World J. Hepatol. 2, 1-7 10.4254/wjh.v2.i1.1
204. Lu, J., Einhorn, S., Venkatarangan, L., Miller, M., Mann, D. A., Watkins, P. B., and LeCluyse, E. (2015) Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing Toxicol. Sci. 147, 39-54 10.1093/toxsci/kfv117
205. Baxter, M., Withey, S., Harrison, S., Segeritz, C. P., Zhang, F., tkinson-Dell, R., Rowe, C., Gerrard, D. T., Sison-Young, R., Jenkins, R., Henry, J., Berry, A. A., Mohamet, L., Best, M., Fenwick, S. W., Malik, H., Kitteringham, N. R., Goldring, C. E., Piper, H. K., Vallier, L., and Hanley, N. A. (2015) Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes J. Hepatol. 62, 581-589 10.1016/j.jhep.2014.10.016
206. Sjogren, A. K., Liljevald, M., Glinghammar, B., Sagemark, J., Li, X. Q., Jonebring, A., Cotgreave, I., Brolen, G., and Andersson, T. B. (2014) Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes Arch. Toxicol. 88, 1427-1437 10.1007/s00204-014-1265-z
207. Takayama, K., Morisaki, Y., Kuno, S., Nagamoto, Y., Harada, K., Furukawa, N., Ohtaka, M., Nishimura, K., Imagawa, K., Sakurai, F., Tachibana, M., Sumazaki, R., Noguchi, E., Nakanishi, M., Hirata, K., Kawabata, K., and Mizuguchi, H. (2014) Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes Proc. Natl. Acad. Sci. U. S. A. 111, 16772-16777 10.1073/pnas.1413481111
208. Pereira, C. V., Oliveira, P. J., Will, Y., and Nadanaciva, S. (2012) Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms Toxicol. Appl. Pharmacol. 264, 167-181 10.1016/j.taap.2012.07.030
209. Klapczynski, M., Gagne, G. D., Morgan, S. J., Larson, K. J., Leroy, B. E., Blomme, E. A., Cox, B. F., and Shek, E. W. (2012) Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models J. Pathol. Inform. 3, 20 10.4103/2153-3539.95456
210. Zabka, T. S., Singh, J., Dhawan, P., Liederer, B. M., Oeh, J., Kauss, M. A., Xiao, Y., Zak, M., Lin, T., McCray, B., La, N., Nguyen, T., Beyer, J., Farman, C., Uppal, H., Dragovich, P. S., O'Brien, T., Sampath, D., and Misner, D. L. (2015) Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase Toxicol. Sci. 144, 163-172 10.1093/toxsci/kfu268
211. Waring, J. F., Liguori, M. J., Luyendyk, J. P., Maddox, J. F., Ganey, P. E., Stachlewitz, R. F., North, C., Blomme, E. A., and Roth, R. A. (2006) Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils J. Pharmacol. Exp. Ther. 316, 1080-1087 10.1124/jpet.105.096347
212. Liguori, M. J., Ditewig, A. C., Maddox, J. F., Luyendyk, J. P., Lehman-McKeeman, L. D., Nelson, D. M., Bhaskaran, V. M., Waring, J. F., Ganey, P. E., Roth, R. A., and Blomme, E. A. (2010) Comparison of TNFalpha to lipopolysaccharide as an inflammagen to characterize the idiosyncratic hepatotoxicity potential of drugs: Trovafloxacin as an example Int. J. Mol. Sci. 11, 4697-4714 10.3390/ijms11114697
213. Iyanagi, T., Watanabe, T., and Uchiyama, Y. (1989) The 3-methylcholanthrene-inducible UDP-glucuronosyltransferase deficiency in the hyperbilirubinemic rat (Gunn rat) is caused by a -1 frameshift mutation J. Biol. Chem. 264, 21302-21307
214. Kempf, D. J., Waring, J. F., Morfitt, D. C., Werner, P., Ebert, B., Mitten, M., Nguyen, B., Randolph, J. T., Degoey, D. A., Klein, L. L., and Marsh, K. (2006) Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors Antimicrob. Agents Chemother. 50, 762-764 10.1128/AAC.50.2.762-764.2006
215. Scheer, N. and Wolf, C. R. (2014) Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications Xenobiotica 44, 96-108 10.3109/00498254.2013.815831
216. Scheer, N., Kapelyukh, Y., Rode, A., Oswald, S., Busch, D., McLaughlin, L. A., Lin, Henderson, C. J., and Wolf, C. R. (2015) Defining Human Pathways of Drug Metabolism In Vivo through the Development of a Multiple Humanized Mouse Model Drug Metab. Dispos. 43, 1679-1690 10.1124/dmd.115.065656
217. Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., and Grompe, M. (2007) Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice Nat. Biotechnol. 25, 903-910 10.1038/nbt1326
218. Peterson, R. A., Krull, D. L., Brown, H. R., and de, S. M. (2010) Morphologic characterization of PhoenixBio (uPA+/+/SCID) humanized liver chimeric mouse model Drug Metab. Lett. 4, 180-184 10.2174/187231210791698456
219. Blomme, E. A., Chinn, K. S., Hardy, M. M., Casler, J. J., Kim, S. H., Opsahl, A. C., Hall, W. A., Trajkovic, D., Khan, K. N., and Tripp, C. S. (2003) Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice Br. J. Dermatol. 148, 211-223 10.1046/j.1365-2133.2003.05065.x
220. Hardy, M. M., Blomme, E. A., Lisowski, A., Chinn, K. S., Jones, A., Harmon, J. M., Opsahl, A., Ornberg, R. L., and Tripp, C. S. (2003) Selective cyclooxygenase-2 inhibition does not alter keratinocyte wound responses in the mouse epidermis after abrasion J. Pharmacol. Exp. Ther. 304, 959-967 10.1124/jpet.102.044545
221. Beauchamp, P., Moritz, W., Kelm, J. M., Ullrich, N. D., Agarkova, I., Anson, B. D., Suter, T. M., and Zuppinger, C. (2015) Development and Characterization of a Scaffold-Free 3D Spheroid Model of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes Tissue Eng., Part C 21, 852-861 10.1089/ten.tec.2014.0376
222. Jahnke, H. G., Steel, D., Fleischer, S., Seidel, D., Kurz, R., Vinz, S., Dahlenborg, K., Sartipy, P., and Robitzki, A. A. (2013) A novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testing PLoS One 8, e68971 10.1371/journal.pone.0068971
223. Ramaiahgari, S. C., den Braver, M. W., Herpers, B., Terpstra, V., Commandeur, J. N., van de Water, B., and Price, L. S. (2014) A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies Arch. Toxicol. 88, 1083-1095 10.1007/s00204-014-1215-9
224. Burkhardt, B., Martinez-Sanchez, J. J., Bachmann, A., Ladurner, R., and Nussler, A. K. (2014) Long-term culture of primary hepatocytes: new matrices and microfluidic devices Hepatol. Int. 8, 14-22 10.1007/s12072-013-9487-3
225. Mueller, D., Kramer, L., Hoffmann, E., Klein, S., and Noor, F. (2014) 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies Toxicol. In Vitro 28, 104-112 10.1016/j.tiv.2013.06.024
226. Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., and Roth, A. (2013) A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity Toxicol. Appl. Pharmacol. 268, 1-16 10.1016/j.taap.2013.01.012
227. Pei, Y., Peng, J., Behl, M., Sipes, N. S., Shockley, K. R., Rao, M. S., Tice, R. R., and Zeng, X. (2015) Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes Brain Res. 10.1016/j.brainres.2015.07.048
228. Sirenko, O., Hesley, J., Rusyn, I., and Cromwell, E. F. (2014) High-content high-throughput assays for characterizing the viability and morphology of human iPSC-derived neuronal cultures Assay Drug Dev. Technol. 12, 536-547 10.1089/adt.2014.592
229. Holmgren, G., Sjogren, A. K., Barragan, I., Sabirsh, A., Sartipy, P., Synnergren, J., Bjorquist, P., Ingelman-Sundberg, M., Andersson, T. B., and Edsbagge, J. (2014) Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes Drug Metab. Dispos. 42, 1401-1406 10.1124/dmd.114.059154
230. Sengupta, S., Johnson, B. P., Swanson, S. A., Stewart, R., Bradfield, C. A., and Thomson, J. A. (2014) Aggregate culture of human embryonic stem cell-derived hepatocytes in suspension are an improved in vitro model for drug metabolism and toxicity testing Toxicol. Sci. 140, 236-245 10.1093/toxsci/kfu069
231. Sirenko, O., Hesley, J., Rusyn, I., and Cromwell, E. F. (2014) High-content assays for hepatotoxicity using induced pluripotent stem cell-derived cells Assay Drug Dev. Technol. 12, 43-54 10.1089/adt.2013.520
232. Clements, M. and Thomas, N. (2014) High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays Toxicol. Sci. 140, 445-461 10.1093/toxsci/kfu084
233. Clements, M., Millar, V., Williams, A., and Kalinka, S. (2015) Bridging Functional and Structural Cardiotoxicity Assays using Human Embryonic Stem-Cell Derived Cardiomyocytes for a more Comprehensive Risk Assessment Toxicol. Sci. 148, 241-260 10.1093/toxsci/kfv180
234. Doherty, K. R., Talbert, D. R., Trusk, P. B., Moran, D. M., Shell, S. A., and Bacus, S. (2015) Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types Toxicol. Appl. Pharmacol. 285, 51-60 10.1016/j.taap.2015.03.008
235. Scott, C. W., Zhang, X., bi-Gerges, N., Lamore, S. D., Abassi, Y. A., and Peters, M. F. (2014) An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility Toxicol. Sci. 142, 331-338 10.1093/toxsci/kfu186
236. Nozaki, Y., Honda, Y., Tsujimoto, S., Watanabe, H., Kunimatsu, T., and Funabashi, H. (2014) Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation Toxicol. Appl. Pharmacol. 278, 72-77 10.1016/j.taap.2014.04.007
237. Shinde, V., Klima, S., Sureshkumar, P. S., Meganathan, K., Jagtap, S., Rempel, E., Rahnenfuhrer, J., Hengstler, J. G., Waldmann, T., Hescheler, J., Leist, M., and Sachinidis, A. (2015) Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation J. Visualized Exp. e52333 10.3791/52333
238. Hou, Z., Zhang, J., Schwartz, M. P., Stewart, R., Page, C. D., Murphy, W. L., and Thomson, J. A. (2013) A human pluripotent stem cell platform for assessing developmental neural toxicity screening Stem Cell Res. Ther. 4, S12 10.1186/scrt373
239. Palmer, J. A., Smith, A. M., Egnash, L. A., Conard, K. R., West, P. R., Burrier, R. E., Donley, E. L., and Kirchner, F. R. (2013) Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening Birth Defects Res., Part B 98, 343-363 10.1002/bdrb.21078
240. Kameoka, S., Babiarz, J., Kolaja, K., and Chiao, E. (2014) A high-throughput screen for teratogens using human pluripotent stem cells Toxicol. Sci. 137, 76-90 10.1093/toxsci/kft239